HUM-MOLGEN events: Theranostics

HUM-MOLGEN -> Events -> Meetings and Conferences

May 14, 2001

SMi Conferences, 52-53 The Hatton, London
12th & 13th September

Day One – 12th September

8.30 Registration & Coffee

9.0 Chairman's Opening Remarks
Chris Stanley, Senior Vice President, Cambridge Pharmaceutical Consultancy

INTRODUCTION

IMPACT OF GENETICS AND GENOMICS ON DIAGNOSTICS AND THERAPEUTICS:
9.10 Opportunities and challenges:
 Opportunities: Better understanding of molecular pathology and drug action
 Opportunities: Developing/choosing more effective medicines
 Opportunities: Predisposition testing-targeted monitoring-early diagnosis - prevention
 Challenges: An enormous amount of clinical data must be collected and analysed
 Challenges: Dialogue with a concerned public
 Challenges: Societal consensus on what use of information to sanction
 Challenges: Set appropriate, realistic expectations
Prof Klaus Lindpaintner, Associate Director, F. Hoffman - La Roche Inc.

THE NEW INDUSTRY OF THERANOSTICS
9.40 Theranostics an overview
 Principles of theranostics
 Implications for the pharmaceutical industry
 Implications for the diagnostic industry
 Potential to provide personalised medicine
 Therapeutic areas & technological developments
 New improvements for clinical trials success and product effectiveness
John Funkhouser, President and Chief Executive Officer, Pharmanetics

IMPLICATIONS OF THERANOSTICS FOR DIAGNOSTIC AND PHARMACEUTICAL INDUSTRIES
10.20 The changing market
 Current trends in drug development
 How will theranostics improve drug design and diagnosis?
 Adapting medicines
 Novel diagnostics for the next generation
 Theranostics – improving drugs and cutting costs?
 Ambitions for the industry
Dr Paul Kelly, Executive Director, President, Chief Executive Officer, Gemini Genomics

PHARMACOGENOMICS

11.00 Morning Coffee

PHARMACOGENOMICS IN THERANOSTICS
11.20 What are the implications of pharmacogenomics?
 Application of pharmacogenomics
 SNP mapping – its potentials and challenges
 DNA probe arrays for pharmacogenomic discovery
 Therapeutic management
 Client implications
 Future for pharmacogenomics
Dr Mark Egerton, Vice President, Incyte Genomics

THE PROMISE OF PROTEOMICS
12.00 How is proteomics different ?
 Where the term proteomics came from
 Haven’t we worked with proteins all along?
 The position of proteomics today and tomorrow
 Development of protein biochips
 Commercialising a proteomic platform through corporate alliances applications
 Market potential for proteomics
Dr. Michael Shi, Senior Director, Applied Genomics, Genometrix

12.40 Lunch

DIAGNOSTICS

IN-VITRO DIAGNOSTIC INDUSTRY
2.00 Tools for discovering the predispositon for disease
 How innovative are these?
 Do they have clinical and social utility?
 Is there cost utility in prevention rather than cure?
 Implications for design and reliability of tests?
 New self-monitoring kits - the key to the future of diagnostics?
 The demise of chronic disease?
Andrew Bufton, Director, External & Regulatory Affairs, Abbott Diagnostics

NOVEL DIAGNOSTIC TECHNOLOGIES
2.40 Therapeutic and diagnostic products for human disease
 Key concepts
 Targeted disease areas
 Non-invasive measurement of blood glucose
 Home use/point of care diagnostic devices
 New extreme sensitivity diagnostic technology with applications in proteomics
 Impact on healthcare sector – better quality of life at less cost
Chris Stanley, Sr. Vice President, Cambridge Pharmaceutical Consultancy

3.20 Afternoon Tea

PREDICTING CANCER
3.40 The “on” and “off” signs for genes
 An overview of the potentials regarding cancer diagnosis
 DNA methylation patterns
 Digitization
 A genetic chip to diagnose disease?
 Population targeting drugs?
 A better future for patients
Alexander Olek, Chief Executive Officer, Epigenomics

NON-INVASIVE TESTING
4.20 Skin cholesterol test for risk assessment and as a theranostic
 The evolution of the skin cholesterol test
 Practical use for the health system
 Implications for patient therapies
 How soon until a home version of cholesterol 1,2,3 test?
 Risk analysis
 Expectations for the future
Dr Brent Norton, President, Chief Executive Officer, International Medical Innovation

5.0 Chairman’s Closing Remarks and Close of Day One

8.30 Re-registration and Coffee

9.00 Chairman's Opening Remarks
Cecilia M. Brown, Marketing Manager, Cytyc UK

MOLECULAR TESTING

MOLECULAR DIAGNOSTIC TESTING
9.10 Current services offered by Molecular Diagnostic Testing
 The current status of molecular diagnostic testing
 Overview of current testing strategies
 Molecular Diagnostics for Point Of Care Testing
 Hurdles and limitations
 Future prospects for molecular diagnostics
Dr. Claire Allan, Head, Molecular Diagnostics, GlaxoSmithKline

NOVEL NUCLEIC ACID AMPLIFICATION ASSAYS
9.40 Customer requirements for third generation amplification technologies
 Automation, Point of care, quantitation
 Applications: SNP detection, blood borne viruses, food microbiology,
m RNA expression, viral load measurement, antibiotic resistance genes
 SMART and SPAR two new isothermal amplification technologies
 Future trends
Bruce Savage, Managing Director, Chief Executive Officer, Cytocell

IN-VITRO THERANOSTICS
10.20 The coming age of in-vitro testing
 A medical reformation
 In-vitro theranostics?
 Application of IVD in Healthcare
 Implications on the clinical laboratory industry
 Growing global market of in-vitro testing
 IVD regulatory issues in Europe
John Place, Director, European Diagnostics Manufacturing Association

THERANOSTIC THERAPIES

11.00 Morning Tea

PREDICTIVE MEDICINE WITH HIV
11.20 The improving diagnostic technology for HIV
 Personalised treatment for Aids patients
 HIV – 1 nucleic acids
 Adverse affects of therapy
 Challenges faced by new technology
 The future for patients
Dr Bob Van Gemen, Chief Executive Officer, PrimaGen

NEW THERAPEUTIC OPPORTUNITIES
12.00 Improving life through personalised medicines:
 Foundations of theranostic testing
 Applications for theranostics
 Current state of genotype-based theranostics
 Theranostics impact on diagnostics
 The potential impact of theranostics on pharmaceutical industries
 Business models that will help to maximise sharing of profits and risks
Dr James Hawkins, President, Hawkins & Associates

12.40 Lunch
AVAILABLE FOR SPONSORSHIP:
For further information of how to take up this targeted marketing opportunity please contact Amanda Hardy
Email: ahardy@smi-online.co.uk
Tel: +44 (0) 20 7827 6700 Fax: +44 (0) 20 7827 67001

2.00 INFECTIOUS DISEASE
Predictive medicine implications on infectious disease
 Overview of theranostics and infectious disease
 Validation of drug targets for infectious disease
 Implications of novel technology for infectious disease
 Future of protein coding for infectious disease
 Challenges faced by new infectious diseases technology
Michel Baijot, Director, Business Development, Innogenetics

PRACTICAL ISSUES

DISEASE MANAGEMENT
2.40 Role of data analysis in predictive medicine
 Improving data collection
 Harnessing treatment selection
 Novel patient monitoring
 A new meaning of diagnosis for patients and doctors
 Future targets?
Joanne Luciano, President, Predictive Medicine, Inc

3.20 Afternoon Tea

WHO PAYS FOR WHAT TESTS?
3.40 considering the consumer first?
 The cost of tests affects whom?
 Faster, smaller, trendier? Is that what the patient/consumer wants?
 Great technology! Are the benefits worth the cost?
 Great idea, you go first!
 Who will pay to prove efficacy?
 Better medicine or Big Brother?
Dr David Robbins, Director of Microarray Applications, ViaLogy

4.20 THE NEW PARADIGM OF PESONALISED MEDICINE

 Evaluating risk before symptoms
 Beyond population-based predictors
 The era of individual empowerment
 The consumerism tidal wave ahead
 Planning for health and productivity
 The bio-informatics infrastructure of the future
 The promise of the paradigm
Dr Ed Balbona, Managing Director, Chief Medical Officer, HealthScreen International

5.00 Chairman's Closing Remarks and Close of Conference

Organized by:

Katy Aldrick

Invited Speakers:

 Prof Klaus Lindpaintner, Associate Director, F.Hoffman - La Roche, Inc.
 Dr Claire Allan, Molecular Diagnostics Programme Manager, GlaxoSmithKline
 Andrew Bufton, Director, External & Regulatory Affairs, Abbott Diagnostics
 Joanne Luciano, President, Predictive Medicine, Inc.
 John Place, Director, European Diagnostics Manufacturing Association
 Chris Stanley, Senior Vice President, Cambridge Pharmaceutical Consultancy
 Dr Brent Norton, President, Chief Executive Officer, International Medical Innovation
 Dr Bob Van Gemen, Chief Executive Officer, PrimaGen
 Dr Paul Kelly, Executive Director, President & Chief Exectutive Officer, Gemini Genomics
 John Funkhouser, President, Pharmanetics
 Dr. Michael Shi, Senior Director, Applied Genomics, Genometrix
 Dr Mark Egerton, Vice President, Incyte Genomics
 Bruce Savage, Managing Director, Chief Executive Officer, Cytocell
 David Robbins, Director, Microarray Applications, Vialogy
 Alexander Olek, Chief Executive Officer, Epigenomics
 Michel Baijot, Director, Business Development, Innogenetics
 Cecilia M. Brown, Marketing Manager, Cytyc UK
 Dr Ed Balbona, Managing Director, Chief Medical Officer, HealthScreen International
 Dr James Hawkins, President, Hawkins & Associates

Deadline for Abstracts:

no abstacts required

Registration:

£1099 + VAT

E-mail:

kaldrick@smi-online.co.uk

Posted by:

Katy Aldrick

Host:

213.38.112.46